Quintiles, SNUH Enter Clinical Research Pact

Quintiles has entered a strategic alliance with the Seoul National University Hospital (SNUH) as part of its Prime Site program. SNUH is Quintiles’ second Prime Site in Asia. Quintiles has six other sites in the U.S., Europe and Africa under the program.

“Prime Sites are large clinical institutions that Quintiles collaborates with to enhance their infrastructure for conducting clinical trials in order to accelerate the development of new and more effective medicines,” explained Michael Klein, M.D., vice president, Quintiles Southeast Asia and South Korea. “SNUH is an ideal partner for us for three reasons: South Korea is an increasingly important player in Asia-Pacific clinical drug development, we have a talented and engaged workforce in South Korea that has a heritage of delivering quality clinical research, and SNUH has embraced a shared vision for this model as we aim to improve human health.”

Professor Yung-Jue Bang, M.D., Ph.D., director of Clinical Trials Center, SNUH, commented, “We are proud of our reputation and experience in conducting international-caliber clinical research across multiple therapeutic areas. We believe that this partnership will help us drive improved productivity and the quality of our clinical research and will place us firmly on the world map as a leading clinical institution.”